Mathias Schmidt
President & Chief Executive Officer ArmaGen & JCR Pharmaceuticals
The Lundquist Institute (TLI) is pleased to welcome Mathias Schmidt, PD, PhD, to its Board of Directors. A life sciences leader with over 25 years of experience in biopharma, Schmidt has dedicated his career to advancing therapies that improve the lives of patients, particularly in rare and pediatric diseases.
Mathias Schmidt currently serves as Chief Executive Officer of ArmaGen, Inc., and as Executive Fellow and Advisor to the Chairman of JCR Pharmaceuticals, Ltd. Over the course of his career, he has led companies through financing rounds, mergers, and international expansion, while keeping patients and outcomes at the center of his work.
At ArmaGen, Schmidt helped advance a blood-brain-barrier platform and guided the first phase II clinical trial of a brain-penetrant therapy for children with severe MPS I. He later expanded JCR’s global rare-disease portfolio and built lasting collaborations across the biopharma ecosystem. Earlier in his career, he held leadership roles at ASTA Medica, Altana, Nycomed, and Takeda California, and trained at MD Anderson Cancer Center in Houston.
Seminars
- Exploring that the rate-limiting step for oligonucleotides targeted for CNS indications is release of oligonucleotides from lysosome and brain tissue
- Evaluating novel delivery technologies across LNPs, ultrasound, viral particles and routes of administration in delivering oligonucleotides to the brain without compromising on potency, distribution, affinity or efficacy
- Reviewing the next step to optimizing structural design to ensure delivery to the cytoplasm and nucleus
